Escin IBCAS# 26339-90-2 |
- beta-Escin
Catalog No.:BCC8172
CAS No.:11072-93-8
- Escin IA
Catalog No.:BCN3862
CAS No.:123748-68-5
- Escin
Catalog No.:BCC8323
CAS No.:6805-41-0
- Sapogenins Glycosides
Catalog No.:BCC5320
CAS No.:8047-15-2
Quality Control & MSDS
Number of papers citing our products
Chemical structure
3D structure
| Cas No. | 26339-90-2 | SDF | Download SDF |
| PubChem ID | 6476031 | Appearance | White powder |
| Formula | C55H86O24 | M.Wt | 1131.3 |
| Type of Compound | Triterpenoids | Storage | Desiccate at -20°C |
| Synonyms | Aescin B | ||
| Solubility | Soluble in ethanol; slightly soluble in water | ||
| Chemical Name | (2S,3S,4S,5R,6R)-6-[[(3S,4S,4aR,6aR,6bS,8R,8aR,9R,10R,12aS,14aR,14bR)-9-acetyloxy-8-hydroxy-4,8a-bis(hydroxymethyl)-4,6a,6b,11,11,14b-hexamethyl-10-[(Z)-2-methylbut-2-enoyl]oxy-1,2,3,4a,5,6,7,8,9,10,12,12a,14,14a-tetradecahydropicen-3-yl]oxy]-4-hydroxy-3,5-bis[[(2S,3R,4S,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy]oxane-2-carboxylic acid | ||
| SMILES | CC=C(C)C(=O)OC1C(C2(C(CC1(C)C)C3=CCC4C5(CCC(C(C5CCC4(C3(CC2O)C)C)(C)CO)OC6C(C(C(C(O6)C(=O)O)OC7C(C(C(C(O7)CO)O)O)O)O)OC8C(C(C(C(O8)CO)O)O)O)C)CO)OC(=O)C | ||
| Standard InChIKey | AXNVHPCVMSNXNP-OXPBSUTMSA-N | ||
| Standard InChI | InChI=1S/C55H86O24/c1-10-23(2)46(71)79-43-44(72-24(3)60)55(22-59)26(17-50(43,4)5)25-11-12-30-51(6)15-14-32(52(7,21-58)29(51)13-16-53(30,8)54(25,9)18-31(55)61)75-49-41(77-48-38(67)36(65)34(63)28(20-57)74-48)39(68)40(42(78-49)45(69)70)76-47-37(66)35(64)33(62)27(19-56)73-47/h10-11,26-44,47-49,56-59,61-68H,12-22H2,1-9H3,(H,69,70)/b23-10-/t26-,27+,28+,29+,30+,31+,32-,33+,34+,35-,36-,37+,38+,39-,40-,41+,42-,43-,44-,47-,48-,49+,51-,52+,53+,54+,55-/m0/s1 | ||
| General tips | For obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while.Stock solution can be stored below -20℃ for several months. We recommend that you prepare and use the solution on the same day. However, if the test schedule requires, the stock solutions can be prepared in advance, and the stock solution must be sealed and stored below -20℃. In general, the stock solution can be kept for several months. Before use, we recommend that you leave the vial at room temperature for at least an hour before opening it. |
||
| About Packaging | 1. The packaging of the product may be reversed during transportation, cause the high purity compounds to adhere to the neck or cap of the vial.Take the vail out of its packaging and shake gently until the compounds fall to the bottom of the vial. 2. For liquid products, please centrifuge at 500xg to gather the liquid to the bottom of the vial. 3. Try to avoid loss or contamination during the experiment. |
||
| Shipping Condition | Packaging according to customer requirements(5mg, 10mg, 20mg and more). Ship via FedEx, DHL, UPS, EMS or other couriers with RT, or blue ice upon request. | ||
| Description | Escin Ib inhibits gastric emptying, at least in part, mediated by capsaicin-sensitive sensory nerves, to stimulate the synthesis and/or release of dopamine, to act through central dopamine2 receptor, which in turn causes the release of PGs. |
| Targets | NO | 5-HT Receptor |
| In vivo | Possible involvement of 5-HT and 5-HT2 receptors in acceleration of gastrointestinal transit by escin Ib in mice.[Pubmed: 10855943]Life Sci. 2000;66(23):2233-8.
|
Escin IB Dilution Calculator
Escin IB Molarity Calculator
| 1 mg | 5 mg | 10 mg | 20 mg | 25 mg | |
| 1 mM | 0.8839 mL | 4.4197 mL | 8.8394 mL | 17.6788 mL | 22.0985 mL |
| 5 mM | 0.1768 mL | 0.8839 mL | 1.7679 mL | 3.5358 mL | 4.4197 mL |
| 10 mM | 0.0884 mL | 0.442 mL | 0.8839 mL | 1.7679 mL | 2.2098 mL |
| 50 mM | 0.0177 mL | 0.0884 mL | 0.1768 mL | 0.3536 mL | 0.442 mL |
| 100 mM | 0.0088 mL | 0.0442 mL | 0.0884 mL | 0.1768 mL | 0.221 mL |
| * Note: If you are in the process of experiment, it's necessary to make the dilution ratios of the samples. The dilution data above is only for reference. Normally, it's can get a better solubility within lower of Concentrations. | |||||
Calcutta University
University of Minnesota
University of Maryland School of Medicine
University of Illinois at Chicago
The Ohio State University
University of Zurich
Harvard University
Colorado State University
Auburn University
Yale University
Worcester Polytechnic Institute
Washington State University
Stanford University
University of Leipzig
Universidade da Beira Interior
The Institute of Cancer Research
Heidelberg University
University of Amsterdam
University of Auckland
TsingHua University
The University of Michigan
Miami University
DRURY University
Jilin University
Fudan University
Wuhan University
Sun Yat-sen University
Universite de Paris
Deemed University
Auckland University
The University of Tokyo
Korea University
- 4-(cis)-Acetyl-3,6,8-trihydroxy-3-methyldihydronaphthalenone
Catalog No.:BCN1468
CAS No.:263368-92-9
- 4-(trans)-Acetyl-3,6,8-trihydroxy-3-methyldihydronaphthalenone
Catalog No.:BCN1469
CAS No.:263368-91-8
- (S)-(-)-Pindolol
Catalog No.:BCC6916
CAS No.:26328-11-0
- Perilloxin
Catalog No.:BCN6614
CAS No.:263249-77-0
- Dehydroperilloxin
Catalog No.:BCN7506
CAS No.:263241-09-4
- 22-Dehydroclerosterol
Catalog No.:BCN5141
CAS No.:26315-07-1
- Pepstatin A
Catalog No.:BCC1218
CAS No.:26305-03-3
- Physcion-8-O-beta-D-monoglucoside
Catalog No.:BCN8511
CAS No.:26296-54-8
- Ficaprenol 11
Catalog No.:BCN5140
CAS No.:26296-50-4
- 2,3',4,6-Tetrahydroxybenzophenone
Catalog No.:BCN5139
CAS No.:26271-33-0
- AICAR
Catalog No.:BCC3606
CAS No.:2627-69-2
- Peritassine A
Catalog No.:BCC9117
CAS No.:262601-67-2
- Aesculuside B
Catalog No.:BCC8115
CAS No.:26339-92-4
- 1,2-Benzisothiazolin-3-one
Catalog No.:BCC8412
CAS No.:2634-33-5
- H-Arg-OMe.2HCl
Catalog No.:BCC2861
CAS No.:26340-89-6
- Rhodojaponin III
Catalog No.:BCN2809
CAS No.:26342-66-5
- H-Lys-OMe .2HCl
Catalog No.:BCC2981
CAS No.:26348-70-9
- Stachysterone D
Catalog No.:BCC8362
CAS No.:26361-67-1
- ESI-09
Catalog No.:BCC5504
CAS No.:263707-16-0
- PPT
Catalog No.:BCC7062
CAS No.:263717-53-9
- EMDT oxalate
Catalog No.:BCC7888
CAS No.:263744-72-5
- Buergerinin G
Catalog No.:BCN4659
CAS No.:263764-83-6
- 3,27-Dihydroxy-20(29)-lupen-28-oic acid methyl ester
Catalog No.:BCN1467
CAS No.:263844-79-7
- 3-Acetoxy-27-hydroxy-20(29)-lupen-28-oic acid methyl ester
Catalog No.:BCN1466
CAS No.:263844-80-0
Possible involvement of 5-HT and 5-HT2 receptors in acceleration of gastrointestinal transit by escin Ib in mice.[Pubmed:10855943]
Life Sci. 2000;66(23):2233-8.
We have reported previously that Escin IB accelerated gastrointestinal transit (GIT) in mice, and that its effect may be mediated by the release of endogenous prostaglandins (PGs) and nitric oxide (NO). In this study, the possible involvement of 5-HT and 5-HT receptors in the GIT acceleration of Escin IB was investigated in mice. The acceleration of GIT by Escin IB (25 or 50 mg/kg, p.o.) was attenuated by pretreatment with ritanserin (0.5-5 mg/kg, s.c., a 5-HT(2A/2C/2B) receptor antagonist), but not with MDL 72222 (1 and 5 mg/kg, s.c.) and metoclopramide (10 mg/kg, s.c.) (5-HT3 receptor antagonists) or tropisetron (1 and 10 mg/kg, s.c., a 5-HT(3/4) receptor antagonist). Furthermore, pretreatment with ketanserin (0.05-5 mg/kg, s.c.), haloperidol (1-5 mg/kg, s.c.) and spiperone (0.5-5 mg/kg, s.c.) (5-HT2A receptor antagonists), as well as a bolus of dl-p-chlorophenylalanine methyl ester (PCPA, 1000 mg/kg, p.o., 1, 6 or 24 h before administration of the sample) (an inhibitor of 5-HT synthesizing enzyme tryptophan hydroxylase) and reserpine (5 mg/kg, p.o.) (a 5-HT depletor), but not 6-hydroxydopamine (80 mg/kg, i.p., a dopamine depletor) or repeated PCPA (300 mg/kg x2, p.o., 72 and 48 h before administration of the sample), also attenuated the effects of Escin IB. It is postulated that Escin IB accelerates GIT, at least in part, by stimulating the synthesis of 5-HT to act through 5-HT2, possibly 5-HT2A receptors, which in turn causes the release of NO and PGs.
